Patients treated with clopidogrel should be carefully monitored for rare but potentially life-threatening hematologic adverse effects, especially during the first 2 to 3 months of therapy.
No takes yet. Share an insight, caveat, or question.
May warrant hematologic monitoring with clopidogrel; leaves open precise incidence from prospective studies.
Balamuthusamy et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: